Evidence mapPaperPMID 41752452Full record

ReviewMolecules (Basel, Switzerland)2026

From PEGylation to Next-Generation Polymers: Overcoming Biological Barriers-A Review.

Rizvangul Iminova, Gulzat Berganayeva, Aliya Zhurtbayeva, Lazzat Abdurakhmanova, Almagul Almabekova, Daniil Shepilov, Gulzira Vassilina, Akmaral Nurmahanova, Gulfairuz Kairalapova, Moldyr Dyusebaeva

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rizvangul IminovaFaculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040/A15E3B4, Kazakhstan.
Gulzat BerganayevaFaculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040/A15E3B4, Kazakhstan.ORCID 0000-0002-7213-7458
Aliya ZhurtbayevaSchool of Pharmacy, Department of Chemistry, Asfendiyarov Kazakh National Medical University, Almaty 050012/A35B8H9, Kazakhstan.
Lazzat AbdurakhmanovaSchool of Pharmacy, Department of Chemistry, Asfendiyarov Kazakh National Medical University, Almaty 050012/A35B8H9, Kazakhstan.
Almagul AlmabekovaSchool of Pharmacy, Department of Chemistry, Asfendiyarov Kazakh National Medical University, Almaty 050012/A35B8H9, Kazakhstan.
Daniil ShepilovFaculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040/A15E3B4, Kazakhstan.ORCID 0009-0003-0471-0587
Gulzira VassilinaFaculty of Biotechnology and Chemical Technologies, Almaty Technological University, Almaty 050012/A05B8Y5, Kazakhstan.
Akmaral NurmahanovaFaculty of Biology and Biotechnology, Al-Farabi Kazakh National University, Almaty 050040/A15E3C7, Kazakhstan.
Gulfairuz KairalapovaFaculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040/A15E3B4, Kazakhstan.
Moldyr DyusebaevaFaculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040/A15E3B4, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(ethylene glycol) (PEG) has long stood as the prevailing standard in drug delivery, celebrated for its capacity to enhance solubility, extend circulation, and improve pharmacological performance. Nevertheless, the emergence of anti-PEG antibodies, accelerated clearance, and limited biodegradability increasingly undermine its role as a universal solution. In response, a new generation of polymers has been developed to address these shortcomings, offering the potential to sustain or surpass PEG's benefits while mitigating immunogenicity, improving biocompatibility, and enabling finer control over therapeutic fate. This review examines current research to articulate a coherent perspective on the replacement of PEG, tracing how advances in polymer design are reshaping the foundations of targeted drug delivery. Taken together, these developments signal not only a corrective to the limitations of PEG but also a broader paradigm shift toward safer, more versatile, and clinically translatable systems that define the next frontier in precision therapeutics.

Indexed as

Drug CarriersDrug Delivery SystemsPolyethylene GlycolsPolymersAnimalsBiocompatible MaterialsHumansBiocompatible MaterialsDrug CarriersPolyethylene GlycolsPolymersbiodegradable polymerslow-immunogenic polymersnanocarriersPEG alternativestargeted cancer therapy

Identifiers

PMID41752452
PMCPMC12943207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.